Treatment with monoclonal antibodies against Clostridium difficile toxins.
By I. Lowy, Deborah C. Molrine, B. Leav, Barbra M. Blair, R. Baxter, D. Gerding, G. Nichol, W. Thomas, M. Leney, S. Sloan and 2 more. New England Journal of Medicine, 2010
723 citations recorded by the source corpus.
Subfields: Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/15261d074681c6161585cf72aec0670654f35767
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling (2014, neutral): “monoclonal antibodies actoxumab and bezlotoxumab (6, 7).”
- European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. (2014, methodology): “Immunotherapy Human monoclonal antibodies against TcdA and TcdB with standard oral antimicrobial therapy (metronidazole and vancomycin) C I [71] Evidence limited to Phase II randomized controlled trial.”
- Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography (2014, background): “difficile toxins is protective both in animal models (29 –32) and in humans (33) demonstrate that TcdA and TcdB are indeed the primary contributors to disease.”
- Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. (2011, background): “RCTs have found monoclonal antibodies to be comparable to metronidazole in preventing recurrence (44% and 45%, respectively) [75] and have found intravenous immunoglobulin to reduce the”